First CRISPR clinical trial backed by U.S. companies launches
The first company-sponsored study of CRISPR-Cas9 in humans has launched, and will test the genome-editing technique in patients with the blood disorder beta thalassemia.
The first clinical trial of CRISPR-Cas9 sponsored by U.S. companies has launched, testing the genome-editing technique in patients with the blood disorder beta thalassemia, according to an announcement posted Friday on the U.S. clinical trials website.
The Phase 1/2 clinical trial, co-sponsored by Vertex Pharmaceuticals and using an experimental treatment from
